After a rough start to the year, small- and mid-cap software stocks may be finding their footing. Goldman Sachs analyst Adam ...

JWST has detected the earliest galaxies in the universe, but some look “more mature” than expected. Is it time to rethink how ...

American barbecue varies depending on the state, but is generally smoked or grilled meat and veg, but what sets Korean ...

Vertex Pharmaceuticals is cranking up the charm on Wall Street with a whopping $4 billion share buyback plan, signaling ...

Google said Gemini has crossed 400 million monthly active users and 7 million developers worldwide are building apps with ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some ...

More on Wilmington Manufacturing: What's made in the Port City? Here are a few things that might surprise you Vertex had hired 105 employees by late September 2015, when the company held a media ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vertex’s Orkambi (lumacaftor+ivacaftor ... It would be the first obesity-targeted GLP-1 in pill form. Boehringer's cystic fibrosis gene therapy is poised to start clinical testing, hoping ...

In a ruling issued on March 31, a federal judge upheld the OIG’s interpretation of the AKS, which formed the basis for the agency issuing an unfavorable advisory opinion to Vertex ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...